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TO THE EDITOR
IL-17A is one of the main pathogenic
factors orchestrating inflammation in
diseases such as psoriasis and rheuma-
toid arthritis (Martin et al., 2012).
Although effective therapies already
exist for these diseases, biologics are
restricted to severely affected patients
due to the considerable costs of current
antibody-based therapies and potential
systemic immunosuppressive and drug-
induced side effects. New topical strate-
gies are therefore required for chronic
inflammation.
Aptamers are considerably cheaper
to produce and furthermore are non-
immunogenic. The use of stable RNA
aptamers for therapy is based on their
ability to fold into unique 3-dimensional
structures that bind to the target with
high specificity and affinity. The first
aptamer-based therapeutic agent, which
targets vascular endothelial growth
factor (Huang et al., 2001), was FDA-
approved in 2004 for treatment of
macular degeneration and several other
aptamers are currently in clinical trials
(Zhou et al., 2012).
Here, we have sought to show the
functional efficacy of a previously des-
cribed aptamer, termed Apt21-2, which
blocks IL-17A binding to its receptor
(Ishiguro et al., 2011). So far, the func-
tional properties of this aptamer have
not been investigated in human patho-
physiological settings. To overcome this
lack of information we analyzed the
efficacy of Apt21-2 in a co-culture
system, which mimics psoriatic inflam-
mation, using T cells isolated from
healthy controls and psoriatic patients.
All human samples were taken in
accordance with the Declaration of
Helsinki Principles, and participants
gave their written informed consent
(ethics approval for this study is covered
by IRAS REC number: 11/YH/0368). This
in-vitro model, using patient-derived and
healthy cells, is based on our own
previous work (Muhr et al., 2010) with
blood-derived IL-17 producers (CD4þ
CCR6þ T cells) activated with TCR
stimulatory antibodies (antiCD3 and
antiCD28; Biolegend, Hatfield, UK).
These cells were co-cultured with
healthy human primary fibroblasts. The
protocols used for the culture of primary
human skin cells are also based on
previous work (Wittmann et al., 2012).
To measure the functional response, a
bead-based ELISA assay (FlowCytomix;
eBioscience, Hatfield, UK) in addition to
an IL-6 and IL-8 ELISA (DuoSet human
ELISA kit; R&D Systems, Abingdon, UK)
was used. IL-17A (Biolegend)-mediated
production of IL-6 was determined to
establish the efficacy of the aptamer, as
this has been employed in the previously
published work (Ishiguro et al., 2011) and
we have extended this to include IL-8. It
is well known that both keratinocytes and
fibroblasts produce IL-6 and IL-8.
Our results confirmed that IL-6
release in recombinant IL-17A-treated
fibroblasts can be significantly abro-
gated in a dose-dependent fashion by
addition of Apt21-2, and this effect
was not seen when a control aptamer
(synthesized to the polymerase from
foot-and-mouth disease virus, 47tr;
Ellingham et al., 2006) was used
(Figure 1a). The effect was also not
present if recombinant tumor necrosis
factor-a (Immunotools, Friesoythe,
Germany) was used as a stimulus
(Figure 1b). The same effect was con-
firmed for fibroblasts isolated from psor-
iatic patients (data not shown). Higher
doses of IL-17A were used and an
efficient inhibitory effect of IL-6 produc-
tion could be seen in doses up to
20 ng ml1. However, the aptamer
failed to consistently neutralize the
effect of 40 ng ml 1 of rIL-17A on IL-6
production in fibroblasts. In a co-culture
system of healthy fibroblasts and healthy
or psoriatic CD4þCCR6þ T cells, a
neutralizing capacity of Apt21-2 wasAccepted article preview online 20 September 2013; published online 24 October 2013
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observed (Figure 1c). A multi-parameter
experiment, using the FlowCytomix
assay on the cell supernatants from the
co-culture experiments, was carried out.
This showed that the neutralizing effect
of the aptamer was most prominent in
reducing IL-6 levels, as shown pre-
viously (Ishiguro et al., 2011), however
a reduction was also seen in levels of
IL-8 and MCP-1 (data not shown).
All experiments carried out in fibro-
blasts were also performed in primary
human keratinocytes. However, the
neutralizing effect was not seen in ker-
atinocytes and the aptamer had no effect
on levels of proinflammatory IL-6 or IL-8
cytokine release (Figure 1d). This led us
to an exploratory experiment using 30-
and 50-labeled Apt21-2 for confocal
microscopy and a 30-labeled Apt21-2
for live-cell imaging. We also included
a labeled control aptamer (47tr). The
results shown in Figure 2 suggest an
efficient uptake of Apt21-2 and 47tr by
primary human keratinocytes, suggest-
ing a nonspecific uptake mechanism.
The lack of availability of the aptamer
in the extracellular space may well
explain the absence of any counter-
regulatory effect on IL-17A-stimulated
keratinocytes.
In summary, our experiments have
confirmed the IL-17A neutralizing
capacity of Apt21-2 in fibroblast culture
and also in fibroblast T–cell cultures.
The best-suited therapeutic approach to
treat skin diseases is to give a site-
specific (i.e., topical) treatment reducing
inflammatory mediators produced by
the keratinocytes. We have shown in
previous work and confirmed in this
study that fibroblasts also have an active
role in production of proinflammatory
mediators. However, a topical treatment
of Apt21-2 would not have neutralizing
effects due to aptamer uptake by upper
skin layer keratinocytes. Therefore,
Apt21-2 would likely not be suitable
for treatment of chronic inflammatory
skin diseases, such as psoriasis, unless
directly introduced into the dermis.
These results are nevertheless extre-
mely interesting as they highlight an
unrecognized function of keratinocytes,
which is their ability to take up RNA
aptamers in a nonspecific manner. Our
experiments show that keratinocytes
appear to take up the RNA aptamer even
in the absence of its target/ligand, sug-
gesting that this process is not specific
for the aptamer target molecule. It has
previously been suggested that uptake of
DNA by skin cells could involve macro-
pinocytosis (Basner-Tschakarjan et al.,
2004; Reyes-Reyes et al., 2010). How-
ever, more work is needed to provide
further information on the mechanisms
of RNA aptamer uptake by keratinocytes
and what cellular mechanisms are at
play. As aptamers have the ability to
specifically modulate protein–protein











































































































































































































































Figure 1. The neutralizing effects of Apt21-2 on recombinant and T-cell-derived IL-17. (a) Effect of increasing concentrations of chemically synthesized
Apt21-2 (n¼ 4) and control aptamer (n¼ 3) on IL-6 production in IL-17A-stimulated primary human dermal fibroblasts. IL-6 values for the positive control (10ng
IL-17A) were set to 100 for each independent experiment to allow summary of neutralization. **Pp0.01, ***Pp0.001. (b) The ability of Apt21-2 to inhibit IL-17A
versus tumor necrosis factor (TNF)-a (as a control) was tested in primary human dermal fibroblasts (n¼ 2). (c) The neutralization was also confirmed in the
co-culture experiment (n¼ 1). (d) Experiments as depicted in a for human primary keratinocytes measuring IL-8 release (n¼ 3). Mean±SEM bars included in a, b,
and d. One-way analysis of variance and Bonferroni tests were performed for each group to assess statistical significance (GraphPad Prism, San Diego, CA).
NS, non-stimulated.
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approach could be further utilized
experimentally as well as therapeu-
tically to target specific intracellular
targets. This function of keratinocytes
could be a potentially invaluable tool
for targeting important proinflammatory
signaling cascades within the epidermal
cellular compartment without the need
for chemical introduction of the RNA
aptamer into these cells. This could be
beneficial when treating inflammation
involving the epidermis using a direct
topical method. RNA aptamers targeting
inflammatory signaling pathways could
present a specific and effective topical
approach, which would not have the
widespread side effects of systemic
therapy.
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Figure 2. Confocal microscopy to track uptake of Apt21-2 in primary human keratinocytes. (a, b) Primary human keratinocytes in the presence of
Cy3-labeled Apt21-2 at 3 hours (a) and 20 hours (b), using live-cell imaging. (c) Primary human keratinocytes were also treated with a Cy3-labeled control aptamer
(47tr) to establish whether the uptake was aptamer specific. DAPI (diamidino-2-phenylindole, top left), Cy3 (top right hand), and merged (lower left).
(d–f) Keratinocytes were also treated with a 30Cy3 and 50Cy5 double-labeled aptamer for 4 hours to confirm that the RNA is intact. Images were taken at
increasing magnification d–f. DAPI (top left), Cy3 (top right hand), Cy5 (lower left), and merged (lower right). Cells were also treated with both 47tr and Apt21-2
in the presence of recombinant IL-17A (data not shown) and no difference in uptake was observed. Bars¼ 50mM.
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TO THE EDITOR
The adult human skin is a highly active
immunological organ containing con-
siderable numbers of T cells (Clark
et al., 2006), which are fundamental
for the maintenance of barrier integrity
and immune surveillance (Kupper
and Fuhlbrigge, 2004). The great
majority of resident T cells exhibit a
memory/effector phenotype and express
the skin-homing marker cutaneous
lymphocyte associated antigen (CLA;
Clark et al., 2006) and several
chemokine receptors (CCR4, CCR6,
CCR8, and CCR10; Campbell et al.,
1999; Homey et al., 2002; Schaerli
et al., 2004; McCully et al., 2012).
The CCR10 ligand CCL27/CTACK
(cutaneous T-cell-attracting chemokine)
is specifically expressed by epidermal
keratinocytes (KCs), and its over-
production is associated with an
enhanced influx of CCR10þCD4þ
T cells into the skin in patients with
inflammatory skin diseases such as
atopic or allergic contact dermatitis
and psoriasis (Homey et al., 2002).
This suggests a distinct role for CCR10
in controlling effector T–cell migration
under specific inflammatory conditions
(Reiss et al., 2001; Homey et al., 2002;
Sigmundsdottir et al., 2007) as opposed
to the recently proposed homeostatic
immune surveillance T-cell trafficking
(McCully et al., 2012). Recently,
Di Nuzzo et al. (2009) reported that,
in contrast to adult skin, fetal human
skin harbors mainly naive CLACD4þ
T cells and less CLAþ T cells.
Confirming and extending this work,
we have shown that only low numbers
of CD3þ T cells (up to 20 times lower
as compared with adult skin) were
present in the skin during midgestation
and only rare T cells during the first
trimester, which were exclusively
located in the dermal compartment
(Schuster et al., 2012). After birth,
memory T cells can be readily
identified in the dermis and in the
epidermis and their number increases
with age (Akgu¨n et al., 2012). As it is
unclear which factors/chemokines
control T-cell immigration into the skin
during ontogeny, we investigated in this
study whether the scarcity of T cells in
prenatal human skin correlates with
CCL27 levels produced by epidermal
KCs. To this purpose, we analyzed its
expression and regulation in prenatal
and adult human KCs in monolayer
and in organotypic skin cultures in vitro.
In line with a previous publication
(Homey et al., 2002), we detected
strong CCL27 expression in adult
epidermis preferentially in basal KCs
and the stratum corneum (Figure 1c,
inset). The specificity of the epidermal
staining was confirmed by blocking
experiments using recombinant CCL27
for pre-absorption of the antibody
(Supplementary Figure S1 online).
CCL27 staining of dermal cells, how-
ever, was not inhibited providing further
evidence for an indirect CCL27 reactiv-
ity of dermal cells via the binding of
CCL27 to its receptor CCR10 as sug-
gested previously (Homey et al., 2002).
In contrast, epidermal CCL27 was
virtually absent in embryonic skin
(12 weeks estimated gestational age
(EGA) (Figure 1a) and was marginally
positive in fetal skin (24 weeks EGA),
showing strongest expression in the
uppermost layer (Figure 1b), indicating
a differentiation-dependent regulation of
CCL27 in KCs. To compare the CCL27
secretory potential of fetal and adult
KCs, we cultured primary KCs for
24 hours in the absence or presence of
the toll-like receptor-3 ligand poly(I:C),
a potent inducer of a variety of chemo-
kines including CCL27 (Lebre et al.,
2007). We found that CCL27 mRNA
was comparably expressed in both,
unstimulated fetal and adult KCs
(Figure 1d, Ct-value¼29), whereas
release of CCL27 protein was detectable
only in adult KCs (Figure 1e). Poly (I:C)
induced a strong increase in CCL27
expression and secretion in adult KCs
and a moderate, although significant,
increase in fetal KCs (Figure 1d and e).
When analyzing lysates of fetal and
adult KCs, we found a significant intra-
cellular expression level of CCL27 not
only in KCs from adult but also from
those of fetal donors (Figure 2c). The
striking differences in the CCL27 stain-
ing pattern between prenatal and adult
skin together with the fact that the
prenatal epidermis is not fully differen-
tiated yet (Dale et al., 1985) promptedAccepted article preview online 13 September 2013; published online 17 October 2013
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